Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-Current Assets (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Non-Current Assets data on record, last reported at $293.1 million in Q4 2025.

  • For Q4 2025, Non-Current Assets rose 5.45% year-over-year to $293.1 million; the TTM value through Dec 2025 reached $1.1 billion, down 1.36%, while the annual FY2025 figure was $293.1 million, 5.45% up from the prior year.
  • Non-Current Assets reached $293.1 million in Q4 2025 per MIRM's latest filing, up from $254.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $293.1 million in Q4 2025 and bottomed at $4.5 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $186.6 million, with a median of $208.6 million recorded in 2022.
  • Peak YoY movement for Non-Current Assets: surged 2736.93% in 2021, then crashed 59.95% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $128.1 million in 2021, then increased by 27.04% to $162.7 million in 2022, then surged by 59.26% to $259.1 million in 2023, then grew by 7.29% to $278.0 million in 2024, then grew by 5.45% to $293.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $293.1 million in Q4 2025, $254.5 million in Q3 2025, and $272.4 million in Q2 2025.